Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.

T Omland, V V Bonarjee, D W Nilsen, J A Sundsfjord, R T Lie, G Thibault, K Dickstein

Medical Department, Central Hospital, Norway.

OBJECTIVE--To evaluate the prognostic significance of plasma N-terminal pro-atrial natriuretic factor (1-98) concentrations measured in the subacute phase after acute myocardial infarction, and to compare the predictive value of measurement of N-terminal pro-atrial natriuretic factor (1-98) with the measurement of atrial natriuretic factor (99-126) and with clinical assessment of the degree of heart failure. DESIGN--Prospective observational. SETTING--Norwegian central hospital. PATIENTS--139 patients (mean (SD) age 66.9 (11.1) years, 71.2% males) with acute myocardial infarction. Patients in cardiogenic shock or with severe heart failure (New York Heart Association class IV) were excluded. MAIN OUTCOME MEASURE--Cardiovascular death within 12 months. RESULTS--During the follow up period 15 patients died. In a univariate Cox proportional hazards model N-terminal pro-atrial natriuretic factor (1-98) was significantly related to mortality (p = 0.0003). In a multivariate model the prognostic value of N-terminal pro-atrial natriuretic factor (1-98) was better than that of atrial natriuretic factor (99-126) and clinical assessment of heart failure (N-terminal pro-atrial natriuretic factor (1-98), p = 0.0003; atrial natriuretic factor (99-126), p = 0.4513; heart failure, p = 0.0719). The odds ratio estimate of patients in whom plasma concentrations of N-terminal pro-atrial natriuretic factor (1-98) were greater than 2000 pmol/l was 25 (95% confidence interval 2.8-225.0) compared with patients with plasma concentrations less than 1000 pmol/l. CONCLUSIONS--These results suggest that determination of plasma N-terminal pro-atrial natriuretic factor (1-98) in the subacute phase of myocardial infarction may provide clinically relevant prognostic information that is superior to that obtained from atrial natriuretic factor (99-126) measurements and clinical evaluation.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ruskoaho, H. (2003). Cardiac Hormones as Diagnostic Tools in Heart Failure. Endocr. Rev. 24: 341-356 [Abstract] [Full Text]  
• Sigurdsson, A., Eriksson, S.V., Hall, C., Kahan, T., Swedberg, K. (2001). Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study. Eur J Heart Fail 3: 69-78 [Abstract] [Full Text]  
• Sagnella, G. A (2000). Practical implications of current natriuretic peptide research. Journal of Renin-Angiotensin-Aldosterone System 1: 304-315  
• Berton, G., Citro, T., Palmieri, R., Petucco, S., Renzo De Toni, S., Palatini, P. (1997). Albumin Excretion Rate Increases During Acute Myocardial Infarction and Strongly Predicts Early Mortality. Circulation 96: 3338-3345 [Abstract] [Full Text]  
• Bonow, R. O. (1996). New Insights Into the Cardiac Natriuretic Peptides. Circulation 93: 1946-1950 [Full Text]  
• Omland, T., Aakvaag, A., Bonarjee, V. V. S., Caidahl, K., Lie, R. T., Nilsen, D. W. T., Sundsfjord, J. A., Dickstein, K. (1996). Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction : Comparison With Plasma Atrial Natriuretic Peptide and N-Terminal Proatrial Natriuretic Peptide. Circulation 93: 1963-1969 [Abstract] [Full Text]